… December 2018. GW is also investigating CBDV for use in epilepsy, though the first clinical trial was not successful. Zynerba studied its transdermal CBD gel ZYNOO2 in Fragile X syndrome ina 12 week Phase || open-label study in children and adolescents. In the trial, patients w...
Results for “Zynerba”
Search across the indexed text of every released document.
Names that match “Zynerba”
3 documents found
and Zynerba’s transdermal CBD gel ZYN002 in Fragile X syndrome.
…mbination). Below we summarize the clinical trial data from GW’s Epidiolex in epilepsy and psychiatric indications, and Zynerba’s transdermal CBD gel ZYNOO2 in Fragile X syndrome. GW conducted a broad Phase III program for Epidiolex in epilepsy, consisting of two Phase Ill trial...